Dexcom (DXCM) | Stock Overview & Key Data

$85.67

-0.98%

| Compare Stocks:

Dexcom vs Abbott Laboratories Dexcom vs Boston Scientific Dexcom vs Stryker Dexcom vs Medtronic plc Dexcom vs Edwards Lifesciences Dexcom vs S&P 500 | Market

Dexcom Performance Comparison

Loading chart data...

Dexcom

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $84.76 High: $86.85

on May 15, 2025

52 Week Range

Low: $57.52 High: $132.26

on April 4, 2025

on May 17, 2024

All-Time High: $164.86 on November 15, 2021

Key Statistics

Market Cap i $33.9B

EPS i 1.33

P/E Ratio (TTM) i 65.05

Forward P/E i 42.62

P/B Ratio i 14.97

PEG Ratio i 42.62

Div. Yield i 0.00%

ROE i 23.72%

Beta i 1.435

Debt to Equity i 113.97

Financial Highlights

Profitability

Gross Margin i 56.85%

Operating Margin i 12.91%

Profit Margin i 12.90%

Returns and Earnings

Return on Assets (TTM) i 5.98%

Return on Equity (TTM) i 23.72%

EBITDA i $975.1M

Net Income (TTM) i $535.2M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Dexcom DXCM	33.93B Large-cap	0.42%	23.79%	-5.34%	12.94%	9.17%	-34.78%	6.67%	-15.44%
Abbott Laboratories ABT	223.67B Mega-cap	-0.46%	5.67%	2.46%	15.08%	17.58%	28.11%	17.76%	45.79%
Boston Scientific BSX	152.31B Large-cap	-1.74%	-2.80%	12.94%	20.38%	12.87%	47.05%	124.84%	173.74%
Stryker SYK	148.31B Large-cap	2.52%	13.06%	1.68%	0.52%	9.30%	17.07%	68.71%	112.78%
Medtronic plc MDT	110.05B Large-cap	2.98%	4.54%	0.05%	-1.62%	7.34%	0.20%	-16.03%	-9.11%
Edwards Lifesciences EW	45.02B Large-cap	0.64%	-0.99%	-4.49%	7.46%	-2.31%	-25.80%	-42.38%	12.52%

Ownership & Short Interest

Insider Ownership i 0.41%

Institutional Ownership i 99.18%

Shares Short i 11M

Short Ratio i 2.47

Short % of Shares Outstanding i 3.73%

Average 10-Day Volume i 5M

Average 90-Day Volume i 5M

Dexcom Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Dexcom would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is DXCM's 52-week high and low?

In the last 52 weeks, Dexcom reached a high of $132.26 (on May 17, 2024) and a low of $57.52 (on April 4, 2025).

What is the market cap and P/E ratio for DXCM?

Curious about Dexcom's size and valuation? Its market capitalization stands at 33.93B. When it comes to valuation, the P/E ratio (trailing twelve months) is 65.05, and the forward P/E (looking ahead) is 42.62.

Does DXCM pay dividends? If so, what's the yield?

As for dividends, Dexcom isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Dexcom's main competitors or similar companies to consider before investing?

When looking at Dexcom, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Abbott Laboratories ABT	223.67B	Healthcare	Medical Devices	28.11%	17.76%
Boston Scientific BSX	152.31B	Healthcare	Medical Devices	47.05%	124.84%
Stryker SYK	148.31B	Healthcare	Medical Devices	17.07%	68.71%
Medtronic plc MDT	110.05B	Healthcare	Medical Devices	0.20%	-16.03%
Edwards Lifesciences EW	45.02B	Healthcare	Medical Devices	-25.80%	-42.38%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Dexcom Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Dexcom's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 23.72%, the Debt to Equity ratio from the most recent quarter is 113.97, and its Gross Profit Margin stands at 56.85%.

What is the recent revenue and earnings growth for DXCM?

Looking at Dexcom's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 12.50%, and quarterly earnings saw a YoY growth of -28.00%.

How much of DXCM stock is held by insiders and institutions?

Wondering who owns Dexcom stock? Company insiders (like executives and directors) hold about 0.41% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.18%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.